English
 
Help Privacy Policy Disclaimer
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT

Released

Journal Article

Crystal structure of FAD-independent methylene-tetrahydrofolate reductase from Mycobacterium hassiacum

MPS-Authors
/persons/resource/persons137633

Demmer,  Ulrike       
Department of Molecular Membrane Biology, Max Planck Institute of Biophysics, Max Planck Society;

/persons/resource/persons137648

Ermler,  Ulrich       
Department of Molecular Membrane Biology, Max Planck Institute of Biophysics, Max Planck Society;

External Resource
No external resources are shared
Fulltext (restricted access)
There are currently no full texts shared for your IP range.
Supplementary Material (public)
There is no public supplementary material available
Citation

Gehl, M., Demmer, U., Ermler, U., & Shima, S. (2023). Crystal structure of FAD-independent methylene-tetrahydrofolate reductase from Mycobacterium hassiacum. Proteins: Structure, Function, and Bioinformatics, 91(9), 1329-1340. doi:10.1002/prot.26504.


Cite as: https://hdl.handle.net/21.11116/0000-000D-0F3B-2
Abstract
FAD-independent methylene-tetrahydrofolate (methylene-H4F) reductase (Mfr), recently identified in mycobacteria, catalyzes the reduction of methylene-H4F to methyl-H4F with NADH as hydride donor by a ternary complex mechanism. This biochemical reaction corresponds to that of the ubiquitous FAD-dependent methylene-H4F reductase (MTHFR), although the latter uses a ping-pong mechanism with FAD as prosthetic group as intermediate hydride carrier. Comparative genomics and genetic analyses indicated that Mfr is indispensable for the growth of Mycobacterium tuberculosis, which lacks the MTHFR-encoding gene. Therefore, Mfr appears to be an excellent target for the design of antimycobacterial drugs. Here, we report the heterologous production, enzymological characterization, and the crystal structure of Mfr from the thermophilic mycobacterium Mycobacterium hassiacum (hMfr), which shows 78% sequence identity to Mfr from M. tuberculosis. Although hMfr and MTHFR have minor sequence identity and different catalytic mechanisms, their structures are highly similar, thus suggesting a divergent evolution of Mfr and MTHFR from a common ancestor. Most of the important active site residues of MTHFR are conserved and equivalently positioned in the tertiary structure of hMfr. The Glu9Gln variant of hMfr exhibits a drastic reduction of the catalytic activity, which supports the predicted function of the glutamate residue as proton donor in both hMfr and MTHFR. Thus, highly similar binding modes for the C1-carriers and the reducing agents in hMfr and MTHFR are assumed.